📊 CLLS Key Takeaways
Is Cellectis S.A. (CLLS) a Good Investment?
Cellectis S.A. is a pre-revenue or early-stage biotech company with critically limited financial data available through SEC EDGAR, making fundamental analysis impossible. The near-complete absence of disclosed financial metrics—including revenue, profitability, assets, and cash position—prevents any meaningful assessment of financial health, operational performance, or sustainability.
Cellectis has a stronger balance sheet than many clinical-stage biotech peers, with $383.5 million of assets, $131.0 million of equity, and roughly $260.3 million of cash plus current financial assets at December 31, 2024; by June 30, 2025, it still reported $226.1 million of cash and deposits and said this should fund operations into the second half of 2027. Fundamentals are improving but still mixed: 2024 net loss narrowed to $36.8 million and first-half 2025 operating loss improved year over year, yet the company remains dependent on collaboration revenue, has no therapeutic product sales, and returned to operating cash burn in 2025.
Why Buy Cellectis S.A. Stock? CLLS Key Strengths
- Operates in high-potential biological products sector with gene editing technology focus
- Nasdaq listing indicates access to capital markets for funding
- No identifiable near-term debt obligations mentioned in available data
- Large liquidity cushion and disclosed runway into the second half of 2027 reduce near-term financing pressure
- 2024 and first-half 2025 showed better operating performance, with higher collaboration revenue and a narrower operating loss in first-half 2025 versus first-half 2024
- Financial obligations appear manageable relative to cash and deposits, supporting continued R&D investment in the pipeline
CLLS Stock Risks: Cellectis S.A. Investment Risks
- Complete lack of revenue or profitability data suggests pre-commercial stage with burn rate concerns
- Inability to assess cash runway or liquidity position poses existential business continuity risk
- Absence of disclosed financial metrics prevents evaluation of R&D spending efficiency and clinical trial progress
- No insider buying activity detected in last 90 days, potentially signaling low management confidence
- Biotech sector inherently high-risk with uncertain regulatory and clinical development outcomes
- Business is still fundamentally unprofitable and has not generated any therapeutic product sales to date
- Revenue quality is weak because it relies heavily on partnerships, milestones, and accounting-driven collaboration recognition rather than recurring commercial demand
- Clinical, regulatory, and funding risk remain high if trials disappoint or cash burn stays elevated and forces new capital raising
Key Metrics to Watch
- Cash position and quarterly burn rate
- Clinical trial progress and regulatory milestones
- Revenue recognition from any approved products or partnerships
- Operating expenses and R&D spending efficiency
- Quarterly operating cash burn versus collaboration cash inflows
- Collaboration revenue conversion and operating loss trend relative to R&D spend
Cellectis S.A. (CLLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CLLS Profit Margin, ROE & Profitability Analysis
CLLS vs Healthcare Sector: How Cellectis S.A. Compares
How Cellectis S.A. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cellectis S.A. Stock Overvalued? CLLS Valuation Analysis 2026
Based on fundamental analysis, Cellectis S.A. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cellectis S.A. Balance Sheet: CLLS Debt, Cash & Liquidity
CLLS Revenue Growth, EPS Growth & YoY Performance
CLLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cellectis S.A. (CIK: 0001627281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLLS
What is the AI rating for CLLS?
Cellectis S.A. (CLLS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLLS's key strengths?
Claude: Operates in high-potential biological products sector with gene editing technology focus. Nasdaq listing indicates access to capital markets for funding. ChatGPT: Large liquidity cushion and disclosed runway into the second half of 2027 reduce near-term financing pressure. 2024 and first-half 2025 showed better operating performance, with higher collaboration revenue and a narrower operating loss in first-half 2025 versus first-half 2024.
What are the risks of investing in CLLS?
Claude: Complete lack of revenue or profitability data suggests pre-commercial stage with burn rate concerns. Inability to assess cash runway or liquidity position poses existential business continuity risk. ChatGPT: Business is still fundamentally unprofitable and has not generated any therapeutic product sales to date. Revenue quality is weak because it relies heavily on partnerships, milestones, and accounting-driven collaboration recognition rather than recurring commercial demand.
What is CLLS's revenue and growth?
Cellectis S.A. reported revenue of N/A.
Does CLLS pay dividends?
Cellectis S.A. does not currently pay dividends.
Where can I find CLLS SEC filings?
Official SEC filings for Cellectis S.A. (CIK: 0001627281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLLS's EPS?
Cellectis S.A. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLLS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cellectis S.A. has a SELL rating with 44% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLLS stock overvalued or undervalued?
Valuation metrics for CLLS: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLLS stock in 2026?
Our dual AI analysis gives Cellectis S.A. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLLS's free cash flow?
Cellectis S.A.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CLLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).